Abliva AB (publ) (OTCMKTS:NEVPF – Get Rating) and Seelos Therapeutics (NASDAQ:SEEL – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Insider and Institutional Ownership

29.6% of Seelos Therapeutics shares are held by institutional investors. 5.1% of Seelos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Abliva AB (publ) and Seelos Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

Seelos Therapeutics has a consensus price target of $4.00, indicating a potential upside of 419.35%. Given Seelos Therapeutics' higher probable upside, analysts plainly believe Seelos Therapeutics is more favorable than Abliva AB (publ).

Valuation and Earnings

This table compares Abliva AB (publ) and Seelos Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Abliva AB (publ) has higher earnings, but lower revenue than Seelos Therapeutics. Seelos Therapeutics is trading at a lower price-to-earnings ratio than Abliva AB (publ), indicating that it is currently the more affordable of the two stocks.

Summary

Seelos Therapeutics beats Abliva AB (publ) on 6 of the 11 factors compared between the two stocks.

About Abliva AB (publ)

(Get Rating)

Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

About Seelos Therapeutics

(Get Rating)

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.

Receive News & Ratings for Abliva AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abliva AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.